CNS Stimulants Flashcards
List the amphetamines (3)
i) DL-amphetamine (Adderall, Speed)
ii) Dextroamphetamine (More potent D-isomer of amphetamine, Dexedrine)
iii) Methamphetamine (Crystal meth)
Amphetamines release monoamines, primarily __________and _________, from nerve terminals in the brain
norepinephrine, dopamine
i) NET =
norepinephrine transporter
ii) DAT =
dopamine active transporter
__________ Enter the sympathetic nerve ending and displace stored NE and DA
i) “Displacer” effect – NE and DA released
Amphetamines
_____________At high concentration – Inhibit monoamine oxidase (MAO)
[MAOs break down DA and NE]
Amphetamines
The main central effects of amphetamine-like drugs are
Locomotor stimulation, Euphoria and excitement, Especially intense with IV injection, Insomnia, Increased stamina, Anorexia
c) Amphetamine Peripheral sympathomimetic effects – rise in _____________, inhibition of ______________
blood pressure, gastrointestinal motility
Amphetamine stimulant effect lasts for a few hours, followed by ______ and ______
depression and anxiety
i) If amphetamines taken repeatedly over a few days
ii) Resembles an acute schizophrenic attack – hallucinations, paranoia and aggressive behavior
iii) Repetitive stereotyped behavior may develop
Amphetamine psychosis
develops rapidly to euphoric and anorexic effects of amphetamines, but more slowly to the other effects.
Tolerance
No clear-cut physical withdrawal syndrome
6) Amphetamines
a) Readily absorbed from the gastrointestinal tract
b) Can be snorted or injected
c) Smoked in crystal form (crystal meth)
d) Freely penetrate the blood–brain barrier
e) Mainly excreted unchanged in the urine
f) The plasma half-life of amphetamines varies from 5 to 30 hours, depending on urine flow
7) Amphetamines PharmacokinetiCs
a) Profound and sustained elevation of extracellular NE and DA
b) Inhibits the NET and DAT transporters
i) (Also inhibits SERT, but with much lower potency)
c) NOT a substrate for NET/DAT transporters –> does not enter the nerve terminals to facilitate NE and DA release
d) Orally active, absorbed from the intestine and colon
Methylphenidate (Ritalin)
Methylphenidate (Ritalin) Clinical use:
e) Clinical use: attention deficit/hyperactivity disorder (ADHD)
a) Increases extracellular DA levels in striatum and nucleus accumbens
i) Likely inhibits DA reuptake by binding to DAT
b) Other effects:
i) enhanced release of 5-HT, glutamate and histamine
ii) inhibition of GABA release
c) Well absorbed from the gut, metabolized in the liver and has a half-life of 10–14 h.
9) Modafinil
d) Used in treatment of narcolepsy
e) Promoted as a ‘wakefulness promoting agent’ rather than a classic amphetamine-like stimulant
f) Reported to ‘brighten mood’
g) Claimed to enhance cognitive performance
h) Effective treatment for ADHD in adults
i) No euphoria when administered by mouth
9) Modafinil
a) 3,4-methylenedioxymethamphetamine, or MDMA
b) Widely used as a party drug
c) Euphoria, loss of inhibitions, and energy surge that it induces
d) Stimulant + mild hallucinogenic effects
Psychotomimetic
e) ______________- affect thought, perception and mood
i) Thoughts and perceptions become distorted and dream-like, rather than being merely sharpened or dulled
Psychotomimetic
e) Psychotomimetic
f) Feelings of empathy and emotional closeness to others (empathogen)
10) MDMA (Ecstasy)
a) An amphetamine derivative
b) Inhibits monoamine transporters, principally the 5-HT transporter
c) Also releases 5-HT
d) large increase in free 5-HT in certain brain regions
i) Similar changes occur in with DA and NE
e) Followed by monoamine depletion
11) MDMA Pharmacological Effects
j) Sudden illness and death can occur even after small doses of MDMA. This can be due to several factors:
Acute hyperthermia
Excess water intake and water retention
heart failure